WO2006017836A3 - 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) - Google Patents

2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) Download PDF

Info

Publication number
WO2006017836A3
WO2006017836A3 PCT/US2005/028191 US2005028191W WO2006017836A3 WO 2006017836 A3 WO2006017836 A3 WO 2006017836A3 US 2005028191 W US2005028191 W US 2005028191W WO 2006017836 A3 WO2006017836 A3 WO 2006017836A3
Authority
WO
WIPO (PCT)
Prior art keywords
bace
secretase
inhibitors
amino
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/028191
Other languages
French (fr)
Other versions
WO2006017836A2 (en
Inventor
Ellen Baxter
Francois Paul Bischoff
Robert Boyd
Mirielle Braeken
Steven Coats
Yifang Huang
Alfonzo Jordan
Chi Luo
Marc Hubert Mercken
Charles H Reynolds
Tina Morgan Ross
Brett A Tounge
Mark Schulz
Winter Hans Louis Jos De
Serge Maria Aloysius Pieters
Allen B Reitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to HR20100595T priority Critical patent/HRP20100595T1/en
Priority to AT05785256T priority patent/ATE483692T1/en
Priority to PL05785256T priority patent/PL1776349T3/en
Priority to DK05785256.8T priority patent/DK1776349T3/en
Priority to EP05785256A priority patent/EP1776349B1/en
Priority to DE602005024004T priority patent/DE602005024004D1/en
Priority to SI200531177T priority patent/SI1776349T1/en
Priority to JP2007525074A priority patent/JP4884387B2/en
Publication of WO2006017836A2 publication Critical patent/WO2006017836A2/en
Publication of WO2006017836A3 publication Critical patent/WO2006017836A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

The present invention is directed to novel 2-amino-3, 4-dihydro­quinazoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD) and related disorders. The compounds of the invention are inhibitors of P-secretase, also known as n-site cleaving enzyme and BACE.
PCT/US2005/028191 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace) Ceased WO2006017836A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
HR20100595T HRP20100595T1 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
AT05785256T ATE483692T1 (en) 2004-08-06 2005-08-08 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS BETA-SECRETASE (BACE) INHIBITORS
PL05785256T PL1776349T3 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
DK05785256.8T DK1776349T3 (en) 2004-08-06 2005-08-08 2-Amino-Puinazoline Derivatives Usable as Inhibitors of Beta-Secretase (BACE)
EP05785256A EP1776349B1 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
DE602005024004T DE602005024004D1 (en) 2004-08-06 2005-08-08 AS BETA SEKRETASE (BACE) HEMMER USEFUL 2-AMINO-CHINAZOLINE DERIVATIVES
SI200531177T SI1776349T1 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)
JP2007525074A JP4884387B2 (en) 2004-08-06 2005-08-08 2-Amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59981104P 2004-08-06 2004-08-06
US60/599,811 2004-08-06

Publications (2)

Publication Number Publication Date
WO2006017836A2 WO2006017836A2 (en) 2006-02-16
WO2006017836A3 true WO2006017836A3 (en) 2006-06-29

Family

ID=35564387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/028191 Ceased WO2006017836A2 (en) 2004-08-06 2005-08-08 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (bace)

Country Status (15)

Country Link
US (1) US8436006B2 (en)
EP (1) EP1776349B1 (en)
JP (1) JP4884387B2 (en)
CN (1) CN101035771A (en)
AT (1) ATE483692T1 (en)
CY (1) CY1111086T1 (en)
DE (1) DE602005024004D1 (en)
DK (1) DK1776349T3 (en)
ES (1) ES2351667T3 (en)
HR (1) HRP20100595T1 (en)
PL (1) PL1776349T3 (en)
PT (1) PT1776349E (en)
RS (1) RS51630B (en)
SI (1) SI1776349T1 (en)
WO (1) WO2006017836A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8829036B2 (en) 2007-02-23 2014-09-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8722708B2 (en) 2005-06-14 2014-05-13 Merck Sharp & Dohme Inc. Substituted isoindolines as aspartyl protease inhibitors
WO2006138264A2 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
ES2360957T3 (en) * 2005-10-25 2011-06-10 Janssen Pharmaceutica Nv DERIVATIVES OF 2-AMINO-3,4-DIHIDRO-PIRIDO (3,4-D) -PIRIMIDINE USEFUL AS INHIBITORS OF THE BETA-SECRETASE (BACE).
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7776882B2 (en) * 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
CA2653650A1 (en) 2006-06-12 2007-12-21 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2009006228A (en) 2006-12-12 2009-06-22 Schering Corp Aspartyl protease inhibitors.
JP5450407B2 (en) 2007-07-06 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted amino-quinazolinones, drugs containing said compounds, their use and methods of manufacture
CN101868457B (en) * 2007-09-24 2013-02-13 科门蒂斯公司 (3-Hydroxy-4-amino-but-2-yl)-3-(2-thiazol-2-yl-pyrrolidin-1-carbonyl)benzamide derivatives for use in therapy as beta-secretase inhibitors and related compounds
AU2008323683B2 (en) * 2007-11-09 2014-10-02 University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for oral administration
WO2009097278A1 (en) * 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
ES2397682T3 (en) * 2008-01-29 2013-03-08 Janssen Pharmaceutica Nv 2-Amino-quinoline derivatives useful as beta-secretase inhibitors (BACE)
AU2009239536C1 (en) 2008-04-22 2012-12-13 Merck Sharp & Dohme Corp. Phenyl-substituted 2-imino-3-methyl pyrrolo pyrimidinone compounds as BACE-1 inhibitors, compositions, and their use
JP2012505241A (en) * 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーション Composition for treating Alzheimer's disease
EP2376083A4 (en) * 2008-11-20 2012-06-20 Purdue Research Foundation Quinazoline inhibitors of bace 1 and methods of using
WO2010065861A2 (en) 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
WO2011063233A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
BR112013026341A2 (en) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. compound, pharmaceutical composition, and method for treating, preventing and / or delaying the onset of a disease or condition
WO2013148130A1 (en) * 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
WO2014127881A1 (en) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino -3,4-dihydro-quinazoline derivatives and the use thereof as cathepsin d inhibitors
AU2019207491A1 (en) 2018-01-10 2020-07-30 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2021007478A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
AR121715A1 (en) 2020-04-03 2022-06-29 Biocryst Pharm Inc PYRROLOPYRIMIDINAMINES AS INHIBITORS OF THE COMPLEMENT SYSTEM

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
JPS63196573A (en) * 1987-02-10 1988-08-15 Dai Ichi Seiyaku Co Ltd Quinazolineacetic acid derivative
EP0406958A2 (en) * 1989-07-07 1991-01-09 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives
WO2004022523A2 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3138595A (en) 1962-12-03 1964-06-23 American Home Prod Nu-(cycloalkyl)-pteridinecarboxamides
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3983120A (en) 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
NL7807507A (en) 1977-07-25 1979-01-29 Hoffmann La Roche TRICYCLICAL CONNECTIONS.
ZA803535B (en) 1979-06-20 1981-06-24 Hoffmann La Roche Novel quinazoline derivatives and pharmaceutical preparations
CA1131631A (en) 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
NZ197420A (en) * 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPS57123184A (en) 1980-12-16 1982-07-31 Hoffmann La Roche Novel manufacture of imidazoquinazolinone derivative
US4455311A (en) 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
ZA826088B (en) 1981-08-28 1983-04-27 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (en) 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd Imidazoquinazoline compound
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
US4783467A (en) 1985-06-05 1988-11-08 Pfizer Inc. Tetrahydroimidazoquinazolinone inotropic agents
GB8514207D0 (en) 1985-06-05 1985-07-10 Pfizer Ltd Cardiac stimulants
JP2544939B2 (en) 1987-09-01 1996-10-16 大塚製薬株式会社 Benzoheterocycle derivative
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH06507782A (en) 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド Non-human recombinant mammals exhibiting amyloid formation symptoms of Alzheimer's disease
JPH04112255A (en) 1990-09-03 1992-04-14 Casio Comput Co Ltd Terminal identifying data setting method
AU652997B2 (en) 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
US5672805A (en) 1991-07-18 1997-09-30 The Regents Of The University Of California Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
AU2765992A (en) 1991-10-03 1993-05-03 Indiana University Foundation Method for screening for alzheimer's disease
DE69233109T2 (en) 1992-01-07 2004-05-19 Elan Pharmaceuticals, Inc., San Francisco TRANSGENIC ANIMAL MODELS FOR ALZHEIMER DISEASE
SE511886C2 (en) 1992-01-31 1999-12-13 Svedala Arbra Ab Way to control a gyratory crusher
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
JPH07132033A (en) 1993-11-12 1995-05-23 Hoechst Japan Ltd Alzheimer's disease model transgenic animal
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2198451A1 (en) 1994-09-01 1996-03-07 Gurparkash Singh Transgenic animal expressing a familial form of human amyloid precursor protein
JPH08151377A (en) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd Quinazoline derivatives
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
IL144461A0 (en) 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
JP2003514900A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1395257A1 (en) 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
ES2287466T3 (en) 2002-03-22 2007-12-16 Janssen Pharmaceutica N.V. DERIVATIVES OF 2-QUINOLINONA AND QUINAZOLINA FROM BENCILIMIDAZOLIL SUBSTITUTED AS INHIBITORS OF FARNESIL TRANSFERASA.
US7262208B2 (en) 2002-04-30 2007-08-28 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of Alzheimer's disease
DE10301105B4 (en) 2003-01-09 2005-11-24 Chemisch-Pharmazeutisches Labor, Rolf Sachse Gmbh Use of 2-amino-2H-quinazoline derivatives for the treatment of myeloproliferative disorders, hypertension and bronchodilation
DE10228103A1 (en) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungicidal active ingredient combinations
EP1407774A1 (en) 2002-09-10 2004-04-14 LION Bioscience AG 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
WO2004082616A2 (en) 2003-03-18 2004-09-30 Merck & Co. Inc. Tetrahydropyranyl cyclopentyl heterocylic amide modulators of chemokine receptor activity
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
GB0325830D0 (en) 2003-11-05 2003-12-10 Novartis Ag Organic compounds
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc Improved leaching of base metals
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CN101035770B (en) 2004-08-06 2011-02-23 詹森药业有限公司 2-Amino-quinazoline derivatives useful as beta-secretase (BACE) inhibitors
PT1789398E (en) 2004-08-06 2010-10-21 Janssen Pharmaceutica Nv 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace)
US8426429B2 (en) 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US20060074105A1 (en) 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
WO2006078577A1 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Tertiary carbinamines having substituted heterocycles, which are active as inhibitors of beta-secretase, for the treatment of alzheimer's disease
ATE498358T1 (en) 2005-06-29 2011-03-15 Compumedics Ltd SENSOR ARRANGEMENT WITH CONDUCTIVE BRIDGE
ES2360957T3 (en) 2005-10-25 2011-06-10 Janssen Pharmaceutica Nv DERIVATIVES OF 2-AMINO-3,4-DIHIDRO-PIRIDO (3,4-D) -PIRIMIDINE USEFUL AS INHIBITORS OF THE BETA-SECRETASE (BACE).
US7932261B2 (en) 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
US7776882B2 (en) 2006-02-06 2010-08-17 Baxter Ellen W 2-amino-3,4-dihydro-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092854A2 (en) 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2009097278A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
ES2397682T3 (en) 2008-01-29 2013-03-08 Janssen Pharmaceutica Nv 2-Amino-quinoline derivatives useful as beta-secretase inhibitors (BACE)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761416A (en) * 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) * 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
JPS63196573A (en) * 1987-02-10 1988-08-15 Dai Ichi Seiyaku Co Ltd Quinazolineacetic acid derivative
EP0406958A2 (en) * 1989-07-07 1991-01-09 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives
WO2004022523A2 (en) * 2002-09-06 2004-03-18 Elan Pharmaceuticals, Inc. 1, 3-diamino-2-hydroxypropane prodrug derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ISHIKAWA, FUMYOSHI ET AL: "Quinazolineacetic acid derivatives as platelet aggregation inhibitors", XP002363713, retrieved from STN Database accession no. 1989:23910 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436006B2 (en) 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8829036B2 (en) 2007-02-23 2014-09-09 Merck Sharp & Dohme Corp. Heterocyclic aspartyl protease inhibitors

Also Published As

Publication number Publication date
HRP20100595T1 (en) 2010-12-31
EP1776349A2 (en) 2007-04-25
CN101035771A (en) 2007-09-12
ATE483692T1 (en) 2010-10-15
DE602005024004D1 (en) 2010-11-18
ES2351667T3 (en) 2011-02-09
RS51630B (en) 2011-08-31
US20060178383A1 (en) 2006-08-10
PT1776349E (en) 2010-12-06
PL1776349T3 (en) 2011-04-29
SI1776349T1 (en) 2011-01-31
DK1776349T3 (en) 2011-01-24
JP2008509165A (en) 2008-03-27
CY1111086T1 (en) 2015-06-11
JP4884387B2 (en) 2012-02-29
EP1776349B1 (en) 2010-10-06
US8436006B2 (en) 2013-05-07
WO2006017836A2 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CY1111086T1 (en) 2-AMINO-KINAZOLIN DERIVATIVE USEFUL FOR BETA-SECRETARISE INHIBITORS (BACE)
CY1111070T1 (en) 2-AMINE-QUINAZOLINE DERIVATIVE USEFUL FOR B-SECRETARISE INHIBITORS (BACE)
WO2007092854A3 (en) 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092846A3 (en) 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004802A3 (en) N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008030412A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004112701A3 (en) Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004069162A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004064778A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004103276A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
IS7925A (en) Hydroxyethylamine derivatives for the treatment of Alzheimer's disease
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2007092839A3 (en) Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
PT1966198E (en) 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of beta-secretase (bace)
WO2006078576A3 (en) Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006057945A3 (en) 2,3,4,6-substituted pyridyl derivative compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005785256

Country of ref document: EP

Ref document number: 2007525074

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 762/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580034122.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005785256

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2010/0564

Country of ref document: RS